Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,833 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 4,229 · Balance 47,833 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 4,375 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,375 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 521 | $729.37 | $380,001.77 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,319 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 521 shares of Company stock on November 15, 2022 at prices ranging from $729.01 to $729.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 361 | $728.44 | $262,966.84 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,840 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 361 shares of Company stock on November 15, 2022 at prices ranging from $728.01 to $728.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 333 | $727.17 | $242,147.61 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,201 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 333 shares of Company stock on November 15, 2022 at prices ranging from $727.02 to $727.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 222 | $726.48 | $161,278.56 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,534 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 222 shares of Company stock on November 15, 2022 at prices ranging from $726.00 to $726.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 57 | $723.19 | $41,221.83 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,756 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 57 shares of Company stock on November 15, 2022 at prices ranging from $723.13 to $723.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 272 | $722.36 | $196,481.92 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,813 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 272 shares of Company stock on November 15, 2022 at prices ranging from $722.26 to $722.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 297 | $721.74 | $214,356.78 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,085 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 297 shares of Company stock on November 15, 2022 at prices ranging from $721.05 to $721.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $720.26 | $2,160.78 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 336 | $719.62 | $241,792.32 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,385 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 336 shares of Company stock on November 15, 2022 at prices ranging from $719.24 to $719.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 109 | $718.60 | $78,327.40 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,721 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 109 shares of Company stock on November 15, 2022 at prices ranging from $718.44 to $718.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · derivative · entry 25 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,280 | $746.00 | $4,684,880.00 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,830 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $179.13 | $1,791,300.00 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,110 Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 86 | $649.54 | $55,860.44 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,470 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 766 | $648.78 | $496,965.48 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,556 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 766 shares of Company stock on August 16, 2022 at prices ranging from $648.17 to $648.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2022 at each separate price. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 701 | $647.73 | $454,058.73 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,322 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 701 shares of Company stock on August 16, 2022 at prices ranging from $647.20 to $647.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2022 at each separate price. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 325 | $646.44 | $210,093.00 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,023 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 325 shares of Company stock on August 16, 2022 at prices ranging from $646.27 to $646.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2022 at each separate price. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 119 | $645.63 | $76,829.97 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,348 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 119 shares of Company stock on August 16, 2022 at prices ranging from $645.49 to $645.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2022 at each separate price. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 332 | $644.49 | $213,970.68 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,467 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 332 shares of Company stock on August 16, 2022 at prices ranging from $644.10 to $644.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2022 at each separate price. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 94 | $643.37 | $60,476.78 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,799 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 94 shares of Company stock on August 16, 2022 at prices ranging from $643.33 to $643.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2022 at each separate price. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 329 | $642.53 | $211,392.37 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,893 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 329 shares of Company stock on August 16, 2022 at prices ranging from $642.13 to $642.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2022 at each separate price. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 537 | $641.47 | $344,469.39 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,222 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 537 shares of Company stock on August 16, 2022 at prices ranging from $641.00 to $641.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2022 at each separate price. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 148 | $640.91 | $94,854.68 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,759 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 148 shares of Company stock on August 16, 2022 at prices ranging from $640.88 to $640.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2022 at each separate price. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 76 | $639.85 | $48,628.60 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,907 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · derivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,487 | $634.25 | $4,114,379.75 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,983 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $179.13 | $1,791,300.00 |
DisclosureSEC source: 0001883850-22-000058 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 57 | $670.49 | $38,217.93 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 17 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,470 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 153 | $669.12 | $102,375.36 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 16 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,527 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 153 shares of Company stock on May 17, 2022 at prices ranging from $669.00 to $669.21. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 180 | $668.68 | $120,362.40 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,680 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 180 shares of Company stock on May 17, 2022 at prices ranging from $668.41 to $668.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 154 | $667.49 | $102,793.46 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 14 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,860 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 154 shares of Company stock on May 17, 2022 at prices ranging from $667.27 to $667.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 352 | $666.23 | $234,512.96 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,014 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 352 shares of Company stock on May 17, 2022 at prices ranging from $666.11 to $666.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 126 | $665.36 | $83,835.36 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,366 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 428 | $664.32 | $284,328.96 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,492 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 428 shares of Company stock on May 17, 2022 at prices ranging from $664.01 to $664.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 472 | $663.60 | $313,219.20 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,920 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 472 shares of Company stock on May 17, 2022 at prices ranging from $663.20 to $663.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 779 | $662.57 | $516,142.03 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,392 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 779 shares of Company stock on May 17, 2022 at prices ranging from $662.29 to $662.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 465 | $661.46 | $307,578.90 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,171 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 465 shares of Company stock on May 17, 2022 at prices ranging from $661.16 to $661.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 77 | $660.32 | $50,844.64 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,636 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 77 shares of Company stock on May 17, 2022 at prices ranging from $660.18 to $660.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 123 | $658.56 | $81,002.88 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,713 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 60 | $657.51 | $39,450.60 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,836 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 58 | $656.52 | $38,078.16 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,896 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 59 | $655.40 | $38,668.60 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,954 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · derivative · entry 19 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,457 | $648.31 | $4,186,137.67 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,013 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $179.13 | $1,791,300.00 |
DisclosureSEC source: 0001883850-22-000046 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 159 | $634.43 | $100,874.37 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,470 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 159 shares of Company stock on February 15, 2022 at prices ranging from $634.23 to $634.56. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 220 | $633.54 | $139,378.80 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,629 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 220 shares of Company stock on February 15, 2022 at prices ranging from $633.26 to $633.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 289 | $632.71 | $182,853.19 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,849 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 289 shares of Company stock on February 15, 2022 at prices ranging from $632.28 to $632.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 185 | $631.67 | $116,858.95 |
DisclosureSEC source: 0001708138-22-000014 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,138 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 185 shares of Company stock on February 15, 2022 at prices ranging from $631.29 to $631.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2022 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.